China smartphone shipments slumped in June on inventory overhang: Jefferies
THE WOODLANDS, TX - Autonomix Medical, Inc. (NASDAQ:AMIX), a micro-cap medical device company currently valued at $4.39 million, announced Monday that the United States Patent and Trademark Office has issued U.S. Patent No. 12,295,646 for its "Smart Torquer and Methods for Using the Same" technology. The company’s stock has shown strong momentum recently, gaining over 10% in the past week.
The newly issued patent covers a smart torquer device designed to enhance manipulation of intravascular devices during minimally invasive procedures while integrating electronic components for mechanical control and data communication.
According to the company, the patented technology includes an engaging mechanism that securely attaches to intravascular devices, a communication module for data exchange, an electrical connection interface for signal transmission, and a manipulator allowing users to apply torque to devices navigating the vascular system.
"This patent strengthens our intellectual property portfolio and reinforces our commitment to developing differentiated technologies that address large and underserved markets," said Brad Hauser, CEO of Autonomix.
The company stated that this patent adds to its portfolio of over 80 issued patents and 40 pending patent applications in nerve-sensing and modulation technologies.
Autonomix’s platform technology utilizes a catheter-based microchip sensing array antenna that the company claims may detect and differentiate neural signals with greater sensitivity than currently available technologies. The system is designed to identify target nerves and then use proprietary RF ablation technology to treat them.
The technology is currently investigational and has not yet received marketing clearance in the United States, according to the press release statement.
In other recent news, Autonomix Medical, Inc. has been granted a U.S. patent for its nerve-sensing medical technology, designed to enhance neurological evaluation and treatment. The patent encompasses systems for locating and mapping electrophysiological signals during neuromodulation procedures, with potential applications in treating conditions like hypertension and chronic pain. Autonomix is also set to expand its clinical trials to include a broader range of visceral cancers, following positive results from an initial trial focused on pancreatic cancer pain. This expansion, known as PoC 2, will evaluate the safety and efficacy of their proprietary ablation technology in mitigating cancer pain and is expected to commence in 2025. The initial trial demonstrated significant pain reduction and decreased opioid use among patients, which has encouraged the company to explore additional cancer indications. Despite these advancements, Autonomix’s technology remains investigational and has not yet received marketing clearance in the United States. The company is optimistic about its platform’s potential to address various diseases involving the nervous system. Investors are advised to consider potential risks and uncertainties as outlined in Autonomix’s filings with the U.S. Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.